Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

As the world waits impatiently for a COVID-19 vaccine, an exhaustive review of hydroxychloroquine and chloroquine pharmacology suggests that the doses used in COVID-19 prevention trials are safe, say University of Oxford affiliated researchers in a study published in PLoS Medicine.

Hand holding pills © 2020 MORU. Photographer: Supa-at Asarath.

“Hydroxychloroquine and chloroquine have become intensely politicised during the COVID-19 pandemic. It has been really hard for the public to separate fact from fiction“  said study co-author Assoc Prof Phaik Yeong Cheah, head of ethics and public engagement at the Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok Thailand.

“There has been a lot of concern that hydroxychloroquine and chloroquine might be toxic, but using pharmacokinetic-pharmacodynamic information from healthy volunteers, patients with malaria and those with rheumatological diseases, as well as people who intentionally took overdoses, we show that the doses used in COVID-19 prevention and most treatment trials are very likely to be safe,” said study co-author Prof Joel Tarning, Head of Clinical Pharmacology at MORU.

Used for over 60 years to treat malaria, amoebic liver abscess and rheumatological conditions like lupus, billions of hydroxychloroquine or chloroquine treatments have been given. These drugs have recently been shown in the laboratory to kill the novel coronavirus (SARS-CoV-2), the virus that causes COVID-19. Hydroxychloroquine does not benefit patients hospitalised with COVID-19 infection, but studies have not examined whether it could work as prevention, where it has a much greater chance of being effective.

Unfortunately, because the whole subject has become so highly charged, say the scientists, large clinical trials like COPCOV – a global study to test if hydroxychloroquine and chloroquine can prevent COVID-19 in healthcare workers – are not being sufficiently promoted or supported. The prevention studies urgently need participants.

“I don’t know if hydroxychloroquine can prevent COVID-19 or not,” said study co-author Prof Sir Nick White, Co-Principal Investigator of the Oxford-led COPCOV clinical trial. “But I do know that we really need to find out, and quickly. All the negative publicity has naturally made people reluctant to enrol in studies. We could be waiting a long time for an effective vaccine.”

COPCOV now has 4 sites operating in the UK, with several more coming on line by end September It is the only non-vaccine COVID prophylaxis study badged as being of Urgent Public Health importance by the UK’s NIHR Clinical Research Network.

“We urge anyone working in UK health settings – nurses, care-assistants, doctors, therapists, dentists, dietitians, cleaners, porters, food service workers, phlebotomists, ambulance workers, radiographers – to go to www.copcov.org and enrol in our UK COVID-19 prevention study,” said Prof Martin Llewelyn from Brighton and Sussex Medical School, who as COPCOV UK’s Chief Investigator leads the Trial in the UK along with Prof Amanda Adler, director of the Diabetes Trials Unit within the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM).

“We know that as used in COPCOV hydroxychloroquine is safe and there are good reasons to think it could offer valuable protection against COVID-19. It’s imperative that COPCOV finds out if it does,” said Prof Llewelyn.

Visit COPCOV UK to register and see which sites are taking part

------------ 

Paper:

COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. White NJ, Watson JA, Hoglund RM, Chan XHS, Cheah PY, Tarning J. PLoS Med 17(9): et003251.

Similar stories

NDM recognizes MORU DPhils students' outstanding research impact

Every year, the Nuffield Department of Medicine (NDM) awards NDM Prizes to its most outstanding graduate research students. MORU was well represented this year, with Mo Yin and Rebecca Inglis highly commended in the category NDM Overall Prize, for conducting research with an outstanding impact. Will Schilling (MORU) received a prize as first year DPhil student.

Congratulations new Associate Professors

Following the meeting of the Medical Sciences Divisional Committee to consider applications for the conferral of the title of Associate Professor, we are pleased to announce that Rashan Haniffa, Dorcas Kamuya, Isabella Oyier, Le Van Tan and Timothy Walker have been awarded the title Associate Professor

COPCOV now world’s largest COVID-19 pre-exposure prophylaxis trial

A 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.

Recruitment surges in COPCOV COVID-19 prevention study

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19

Simple blood tests may help improve malaria diagnosis in clinical studies

About one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.